Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v3-EN
Language English English
Date Updated 2017-04-12 2017-03-28
Drug Identification Number 02148706 02148706
Brand name NALOXONE HCL INJECTION - 0.4MG/ML USP NALOXONE HCL INJECTION - 0.4MG/ML USP
Common or Proper name NALOXONE NALOXONE
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients NALOXONE HYDROCHLORIDE NALOXONE HYDROCHLORIDE
Strength(s) 0.4MG 0.4MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 10ML VIAL 10ML VIAL
ATC code V03AB V03AB
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2017-03-27 2017-03-27
Actual start date
Estimated end date 2017-06-16 2017-04-28
Actual end date 2017-04-11
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments